Ticker Details
Gilead Sciences, Inc. Gilead Sciences Inc is a biopharmaceutical company that discovers, develops and commercializes new medicines in areas of unmet medical need. Its products target a number of areas, such as HIV, liver diseases, cardiovascular and other diseases.
IPO Date:	January 3, 1994
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$187.84B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.75 | 1.13%
Avg Daily Range (30 D):	$2.17 | 1.57%
Avg Daily Range (90 D):	$1.73 | 1.35%

Institutional Daily Volume
Avg Daily Volume:	9.61M
Avg Daily Volume (30 D):	6.07M
Avg Daily Volume (90 D):	5.21M

Trade Size
Avg Trade Size (Sh.):	179
Avg Trade Size (Sh.) (30 D):	64
Avg Trade Size (Sh.) (90 D):	60

Institutional Trades
Total Institutional Trades:	123,115
Avg Institutional Trade:	$5.42M
Avg Institutional Trade (30 D):	$17.96M
Avg Institutional Trade (90 D):	$16.95M
Avg Institutional Trade Volume:	.12M
Avg Institutional Trades (Per Day):	21

Market Closing Trades
Avg Closing Trade:	$57.43M
Avg Closing Trade (30 D):	$199.1M
Avg Closing Trade (90 D):	$173.03M
Avg Closing Volume:	853.02K

News

Feb 23, 2026 @ 3:48 PM Arcellx Surges as Gilead’s $7.8B Offer Lock... Source: Timothy Fries

Feb 23, 2026 @ 12:51 PM Gilead Buys Arcellx To Fast-Track Next-Gen Myeloma... Source: Vandana Singh

Feb 12, 2026 @ 2:34 AM Xilio Therapeutics Announces Pricing of Underwritt... Source: Not Specified

Feb 11, 2026 @ 7:23 PM Software Slump Resumes, Bitcoin Plunges To $66,000... Source: Piero Cingari

Feb 11, 2026 @ 9:00 AM Hepatitis B Treatment Market Size is Projected to ... Source: Sns Insider

Financials
	TTM	Q3 2025	Q2 2025
Basic EPS	$6.5	$2.46	$1.57
Diluted EPS	$6.46	$2.43	$1.56
Revenue	$29.09B	$7.77B	$7.08B
Gross Profit	$22.9B	$6.2B	$5.58B
Net Income / Loss	$8.11B	$3.05B	$1.96B
Operating Income / Loss	$10.49B	$3.33B	$2.47B
Cost of Revenue	$6.19B	$1.57B	$1.5B
Net Cash Flow	$2.29B	$2.19B	$-2783M
PE Ratio	22.77

Splits
Jan 28, 2013	2:1
Jun 25, 2007	2:1
Sep 07, 2004	2:1
Mar 08, 2002	2:1
Feb 22, 2001	2:1